Advances in Therapy 2012; 29(12)., Curtis BH, , . A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin.
Roze S, Kurth H, Medical Devices: Evidence and Research 2012; 5: 97-101., , Marty R. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries.
Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Journal of Medical Economics 2012., Eiermann W. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Journal of Medical Economics 2012; 15(5): 977-86., Fajardo-Montañana C, , Ericsson A, . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
Journal of Medical Economics 2012; 15(4): 766-75., Curtis BH, . A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
Diabetic Medicine 2012; 29(3): 303-12., Jendle J, Saraheimo M, Thorsteinsson B, , Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
Davies MJ, Chubb BD, Smith IC, Diabetic Medicine 2012; 29(3): 313-20.. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.